Skip to content

Released Aug 8, 2024, before the open

10-Q filed Aug 8, 2024, 39 days after period end · 0001628280-24-035867

Q2 2024 · 10-Q
Revenue$6.89M+23.0% vs Q2 2023+36.4% vs Q1 2024
Net Income-$22.98MN/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$0.45N/M vs Q2 2023N/M vs Q1 2024
Operating Income-$26,632,000N/M
Operating Cash Flowderived-$25,537,000N/M
Free Cash Flowderived-$25,554,000N/M
Margins · derived
Operating margin-386.6%+185.8 pt vs Q2 2023
Net margin-333.6%+193.0 pt vs Q2 2023

What the release said

The release

Same quarter

MetricQ2 2024Q2 2023Q2 2022Q2 2021
Revenue$6.89M$5.60M$4.49M$279.00K
Net Income-$22.98M-$29.49M-$27.31M-$23.11M
EPS Diluted-$0.45-$0.70-$0.66-$0.63

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR